Abstract
We modeled the viral dynamics of 13 untreated patients infected with SARS-CoV-2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than 2 logs, drug efficacy needs to be greater than 90% if treatment is administered after symptom onset; an efficacy of 60% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 6-87% efficacy. They may help control virus if administered very early, but may not have a major effect in severe patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Antonio Gonçalves was funded by a grant from Roche Pharmaceutical Research and Early Development. Portions of this work were done under the auspices of the U.S. Department of Energy under contract 89233218CNA000001. We also gratefully acknowledge the support of the U.S. Department of Energy through the LANL/LDRD Program for this work as well as N.I.H. grants R01 AI028433, R01 OD011095, R01 AI078881 and P01 AI131365 (ASP).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest Jérémie Guedj has consulted for F. Hoffman-La Roche. All other authors declared no competing interests for this work.
Ethical statement Data were originally provided in Young et al. (doi:10.1001/jama.2020.3204) where “waiver of informed consent for collection of clinical data from infected individuals was granted by the Ministry of Health, Singapore” and “written informed consent was obtained from study participants”.
Funding statement Antonio Gonçalves is funded by a grant from Roche Pharmaceutical Research and Early Development. The study has received financial support of the national research agency (ANR) through the ANR-Flash calls for COVID-19 (TheraCoV ANR-20-COVI-0018). Portions of this work were done under the auspices of the U.S. Department of Energy under contract 89233218CNA000001. We also gratefully acknowledge the support of the U.S. Department of Energy through the LANL/LDRD Program for this work (ASP, RK).
Data Availability
Data were originally provided in Young et al. doi:10.1001/jama.2020.3204 "where written informed consent was obtained from study participants for collection of biological samples after review and approval of the study protocol by the institutional ethics committee"
